dabigatran has been researched along with Cirrhosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Annaldas, S; Godugu, C; Saifi, MA | 1 |
| Dong, A; Morris, A; Mueller, P; Smyth, SS; Yang, F; Yang, L | 1 |
| Crijns, HJ; De Boer, HC; De Jong, AM; Kamphuisen, PW; Kuiper, M; Lau, DH; Linz, D; Lumeij, S; Maass, AH; Rienstra, M; Schotten, U; Spronk, HM; Ten Cate, H; Van Gelder, IC; van Hunnik, A; van Zonneveld, AJ; Verheule, S; Zeemering, S | 1 |
3 other study(ies) available for dabigatran and Cirrhosis
| Article | Year |
|---|---|
A direct thrombin inhibitor, dabigatran etexilate protects from renal fibrosis by inhibiting protease activated receptor-1.
Topics: Animals; Antithrombins; Collagen Type I; Dabigatran; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibrosis; Kidney; Kidney Diseases; Male; Mice; Oxidative Stress; Receptor, PAR-1; Signal Transduction; Snail Family Transcription Factors; Transforming Growth Factor beta; Ureteral Obstruction | 2021 |
Direct thrombin inhibition with dabigatran attenuates pressure overload-induced cardiac fibrosis and dysfunction in mice.
Topics: Animals; Dabigatran; Disease Models, Animal; Fibrosis; Humans; Male; Mice; Myocardium; Thrombin | 2017 |
Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
Topics: Analysis of Variance; Animals; Antithrombins; Atrial Fibrillation; Cell Proliferation; Dabigatran; Female; Fibrinolytic Agents; Fibroblasts; Fibrosis; Goats; Heart Atria; Indazoles; Mice, Transgenic; Nadroparin; Peptide Hydrolases; Pyrroles; Quinazolines; Rats; Receptors, Thrombin; Thrombin; Thrombophilia; Urea | 2017 |